Mphasis Ltd Share Price – NSE  /  BSE

IT - Software, Small Cap

The key equity indices ended with robust gains on Friday, snapping a five-day declining streak. The Nifty settled above the 24,800 level. All the sectoral indices on the NSE ended in green.

As per provisional closing, the barometer index, the S&P BSE Sensex jumped 1,292.92 points or 1.62% to 81,332.72. The Nifty 50 index soared 428.75 points or 1.76% to 24,834.85. The Nifty 50 clocked an all-time high of 24,861.15 in late trade.

In the broader market, the S&P BSE Mid-Cap index rallied 2.12% and the S&P BSE Small-Cap index added 1%.

The market breadth was strong. On the BSE, 2,650 shares rose and 1,285 shares fell. A total of 105 shares were unchanged.

The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, declined 2.93% to 12.25.

New Listing:

Shares of Sanstar ended at Rs 115.36 on the BSE, representing a premium of 12.43% as compared with the issue price of Rs 95.

The scrip was listed at Rs 106.40, exhibiting a premium of 12% to the issue price.

The stock has hit a high of 127.68 and a low of 106.40. On the BSE, over 103.42 lakh shares of the company were traded in the counter.

Sanstar's IPO was subscribed 82.99 times. The issue opened for bidding on 19 July 2024 and it closed on 23 July 2024. The price band of the IPO was fixed at Rs 90 to 95 per share.

Buzzing Index:

The Nifty Metal index rallied 3.01% to 9,423.40. The index declined 1.09% in the past trading session.

Vedanta (up 3.79%), Jindal Steel & Power (up 3.65%), NMDC (up 3.49%), Steel Authority of India (up 3.38%), Adani Enterprises (up 3.34%), Tata Steel (up 3.34%), Hindalco Industries (up 3.17%), National Aluminium Company (up 3.08%), JSW Steel (up 2.8%) and Ratnamani Metals & Tubes (up 2.33%) advanced.

On the other hand, Hindustan Zinc (down 0.83%) edged lower.

Stocks in Spotlight:

Tech Mahindra rose 0.78%. The IT major's consolidated net profit jumped 28.82% to Rs 851.5 crore on 1.04% rise in revenue from operations to Rs 13,005.5 crore in Q1 FY25 over in Q1 FY24. On a year on year (YoY) basis, Tech Mahindra's net profit grew 22.96% while revenue fell 1.17% in first quarter of FY25.

Cipla rallied 5.32% to Rs 1,579.65 after the pharma major’s consolidated net profit jumped 18.27% to Rs 1177.64 crore in Q1 FY25 as against Rs 995.70 crore reported in Q1 FY24. Total revenue from operations grew by 5.77% year on year to Rs 6693.94 crore in the quarter ended 30 June 2024.

Mphasis jumped 6.02% after the company's consolidated net profit grew 2.87% to Rs 404.51 crore in Q1 FY25 as compared with Rs 393.22 crore in Q4 FY24. Revenue from operations rose marginally to Rs 3,422.46 crore in Q1 FY25 as against Rs 3,412.05 crore posted in Q4 FY24.

Cyient dropped 5.46% after the IT major reported 23.94% fall in consolidated net profit to Rs 143.9 crore on 9.94% decline in revenue from operations to Rs 1,675.7 crore in Q1 FY25 over Q4 FY24.

DLF advanced 1.94% after the realty major’s consolidated net profit increased 22.51% to Rs 645.61 crore in Q1 FY25 as compared with Rs 527 crore recorded in Q1 FY24. Revenue from operations fell 4.28% year on year (YoY) to Rs 1,362.35 crore in the quarter ended 30 June 2024.

United Breweries declined 3.24%. The company's consolidated net profit jumped 27.41% to Rs 173.55 crore in Q1 FY25 as compared to Rs 136.21 crore posted in corresponding quarter last year. Revenue from operations (excluding excise duty) rose 8.81% YoY to Rs 2,475.13 crore in June 2024 quarter, driven by 5% volume growth led by 44% growth in the premium segment, further fueled by pricing.

SJVN zoomed 5.07% after the company received a letter of intent (LOI) for allotment of Darzo Lui Pumped Storage Project from the Government of Mizoram. The estimated cost of project on completion is Rs 13,947.50 crore including IDC & Financing costs at April 2023 Price Level. This is the first project of the company in the state of Mizoram.

Sun Pharmaceutical Industries gained 3.41% after the pharma major said that it has received approval from the U.S. Food and Drug Administration (US FDA) for LEQSELVI (deuruxolitinib), an oral JAK Inhibitor for the treatment of severe alopecia areata.

Glenmark Life Sciences declined 2% to Rs 858.20 after the company’s standalone net profit declined 17.69% to Rs 111.48 core in Q1 FY25 as compared with Rs 135.45 crore in Q1 FY24. Revenue from operations rose 1.75% YoY to Rs 588.62 crore in the first quarter of FY25.

Global Markets:

European shares advanced on Friday as investors awaited key U.S. economic figures.

Most Asian stocks ended higher as traders digested Tokyo's latest inflation data. Japan’s headline inflation eased slightly to 2.2% in July, while core inflation held steady at 2.2%.

The market's focus now shifts to the U.S., where the release of the personal consumption expenditure (PCE) index – the Federal Reserve's preferred inflation gauge – is expected to influence interest rate expectations.

Meanwhile, U.S. stocks experienced a rotation away from technology shares on Thursday, with the Nasdaq Composite and S&P 500 declining. The Dow Jones Industrial Average bucked the trend with a modest gain. This shift is a common occurrence during bull markets as market leadership evolves.

Powered by Capital Market - Live News

Revenue from operations rose marginally to Rs 3,422.46 crore in Q1 FY25 as against Rs 3,412.05 crore posted in Q4 FY24.

As compared with Q1 FY24, the company's net profit increased 2.13% while revenue grew by 5.24% in Q1 FY25.

Profit before tax was at Rs 537.32 crore in quarter ended 30 June 2024 (up 2.87% QoQ and up 2.2% YoY).

The company’s gross revenue increased 0.2% QoQ and 4.6% YoY in Q1 FY25 on reported basis and declined 0.1% QoQ and grew 3.1% YoY in constant currency.

Direct revenue grew 0.6% QoQ and 5.6% YoY on reported basis and grew 0.3% QoQ and 4.1% YoY in constant currency.

New total contact value (TCV) stood at $319 million in Q1 FY25 in Direct, of which 84% were in the new-gen services.

Nitin Rakesh, chief executive officer, and managing director, Mphasis, said, “As AI-enabled platforms are adopted at scale and infused across all deal archetypes and solutions, we continue to witness a strong growth momentum in Artificial Intelligence (AI) powered deals by leveraging our ‘Savings led TransformationTM’ theme. We are seeing a steady improvement in client demand, and with the strength of our deal pipeline, we remain cautiously optimistic that this trend will continue to improve in our core markets.”

Mphasis is an information technology (IT) solutions provider specializing in cloud and cognitive services.

Powered by Capital Market - Live News

Mphasis announced the launch of Mphasis NeoCrux™, an industry-first tool designed to improve software engineer's productivity by streamlining the Software Development Lifecycle with the help of Generative AI (Gen AI) powered Agent Orchestrator. This is one of the first platforms in the market that provides flexibility to engineers to integrate fit-for-purpose AI Agents instead of limiting their access to one AI agent. In addition to NeoCrux, Mphasis also launched the only Gen AI-based Enterprise Modernization Platform in the marketplace, NeoZeta&trade, that offers full transparency into the re-learning process so organizations can modernize mission-critical systems with confidence.

Mphasis NeoCrux and NeoZeta are game changers for engineers and enterprises, said Ramanathan Srikumar, Chief Solutions Officer, Mphasis. “Revolutionizing the development landscape, Mphasis NeoCrux bridges the gap between innovation and efficiency by seamlessly integrating essential tools and harnessing the transformative capabilities of Gen AI agents. At the same time, NeoZeta transforms enterprise application modernization by unlocking hidden knowledge in code, non-code artifacts like architecture documents, meeting transcripts etc. Together, these platforms empower its users to focus on innovation while enhancing personalized experiences and delivering exceptional software solutions more efficiently for enterprises.

Powered by Capital Market - Live News

Net profit of Mphasis rose 2.14% to Rs 404.51 crore in the quarter ended June 2024 as against Rs 396.05 crore during the previous quarter ended June 2023. Sales rose 5.24% to Rs 3422.46 crore in the quarter ended June 2024 as against Rs 3252.01 crore during the previous quarter ended June 2023.

Powered by Capital Market - Live News